Implications of bedaquiline-resistant tuberculosis
- PMID: 35092789
- DOI: 10.1016/S1473-3099(22)00008-1
Implications of bedaquiline-resistant tuberculosis
Conflict of interest statement
We declare no competing interests.
Comment in
-
Implications of bedaquiline-resistant tuberculosis.Lancet Infect Dis. 2022 Feb;22(2):166. doi: 10.1016/S1473-3099(22)00007-X. Lancet Infect Dis. 2022. PMID: 35092790 No abstract available.
Comment on
-
Assessment of epidemiological and genetic characteristics and clinical outcomes of resistance to bedaquiline in patients treated for rifampicin-resistant tuberculosis: a cross-sectional and longitudinal study.Lancet Infect Dis. 2022 Apr;22(4):496-506. doi: 10.1016/S1473-3099(21)00470-9. Epub 2021 Nov 12. Lancet Infect Dis. 2022. PMID: 34780706
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources